Arbutus Biopharma (ABUS) – Press Releases
-
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
-
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
-
Arbutus to Participate in Two Upcoming Investor Conferences
-
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
-
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
-
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
-
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
-
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
-
Arbutus to Present at Jefferies London Healthcare Conference
-
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
-
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
-
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
-
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
-
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
-
Arbutus to Participate in Two Upcoming Investor Conferences
-
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
-
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
-
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
-
Arbutus Appoints Two New Executives
-
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
-
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
-
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
-
Arbutus to Present at Jefferies Healthcare Conference
-
Arbutus to Present at JMP Securities Life Sciences Conference
-
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
-
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
-
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
-
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
-
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
-
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
-
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
-
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
-
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
-
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
-
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
-
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
-
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
-
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
-
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
-
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
-
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
-
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
-
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
-
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
-
Arbutus to Participate in Three Upcoming Investor Conferences
-
Arbutus to Participate in Three Upcoming Investor Conferences
-
Arbutus Announces Resignation of Board Member
-
Arbutus Announces Resignation of Board Member
-
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
Back to ABUS Stock Lookup
